Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum

Clinical Therapeutics

Volumn 30, Issue PART 2, 2008, Pages 2181-2190

  Chrysant, Steven G ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

angiotensin receptor blockers; cardiovascular disease continuum; hypertension; renin angiotensin system; risk reduction

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; IRBESARTAN; LOSARTAN; NITRENDIPINE; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ARTICLE; BRAIN PROTECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG POTENTIATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; STROKE; UNSPECIFIED SIDE EFFECT;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOVASCULAR DISEASES; CREATININE; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; STROKE;

EID: 61549137833     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.002     Document Type: Article

References (60)

1. Dzau V., and Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. Am Heart J 121 (1991) 1244-1263
2. Dzau V.J., Antman E.M., Black H.R., et al. The cardiovascular disease continuum validated: Clinical evidence of improved patient outcomes: Part 1: Pathophysiology and clinical trial evidence (Risk factors through stable coronary artery disease). Circulation 114 (2006) 2850-2870
3. Kosaka K., Noda M., and Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: A Japanese trial in IGT males. Diabetes Res Clin Pract 67 (2005) 152-162
4. Eriksson K.F., and Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise. Diabetologia 41 (1998) 1010-1016
5. Chiasson J.L., Josse R.G., Gomis R., et al., for the STOPNIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
6. Turnbull F., Neal B., Algert C., et al., for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005) 1410-1419
7. Turnbull F., Neal B., Ninomiya T., et al., for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials. BMJ 336 (2008) 1121-1123
8. Turnbull F., Woodward M., Neal B., et al., for the Blood Pressure Lowering Treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 29 (2008) 2669-2680
9. Boutitie F., Oprisiu R., Achard J.M., et al. Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens 25 (2007) 1543-1553
10. Ong K.L., Cheung B.M., Man Y.B., et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49 (2007) 69-75
11. Lewington S., Clarke R., Qizilbash N., et al., for the Prospective Studies Collaboration. Age-specific rele vance of usual blood pressure to vascular mortality: A meta-analysis of individual data from one million adults in 61 prospective studies [published correction appears in Lancet. 2003;361:1060]. Lancet 360 (2002) 1903-1913
12. Staessen J.A., Li Y., Thijs L., and Wang J.G. Blood pressure reduction and cardiovascular prevention: An update including the 2003-2004 secondary prevention trials. Hypertens Res 28 (2005) 385-407
13. Turnbull F., Neal B., Pfeffer M., et al., for the Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system [published correction appears in J Hypertens. 2007;25:1524]. J Hypertens 25 (2007) 951-958
14. Chobanian A.V., Bakris G.L., Black H.R., et al., for the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National Heart, Lung, and Blood Institute; and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 12061252
15. Mancia G., De Backer G., Dominiczak A., et al., for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [published correction appears in J Hypertens. 2007;25:1749]. J Hypertens 25 (2007) 1105-1187
16. Zanchetti A., Hansson L., Ménard J., et al. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) Study. J Hypertens 19 (2001) 819-825
17. Staessen J.A., Thijs L., Fagard R., et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 22 (2004) 847-857
18. Julius S., Nesbitt S.D., Egan B.M., et al., for the Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006) 1685-1697
19. Lüders S., Schrader J., Berger J., et al., for the PHARAO Study Group. The PHARAO study: Prevention of hypertension with the angiotensinconverting enzyme inhibitor ramipril in patients with high-normal blood pressure: A prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26 (2008) 1487-1496
20. Moser M., and Hebert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 27 (1996) 1214-1218
21. Tocci G., Sciarretta S., and Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 26 (2008) 1477-1486
22. Haider A.W., Larson M.G., Franklin S.S., Levy D., and for the Framingham Heart Study. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 138 (2003) 10-16
23. Chrysant S.G. Vascular remodeling: The role of angiotensin-converting enzyme inhibitors. Am Heart J 135 (1998) S21-S30
24. Dzau V. The cardiovascular continuum and renin-angiotensinaldosterone system blockade. J Hypertens Suppl 23 (2005) S9-S17
25. Fliser D., Buchholz K., Haller H., and for the European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (2004) 1103-1107
26. Williams B., Lacy P.S., Thom S.M., et al., for the CAFE Investigators, the Anglo-Scandinavian Cardiac Out comes Trial Investigators, the CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 113 (2006) 1213-1225
27. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al., for the LIFE Study Group. Cardiovascular morbidity and mor tality in the Losartan Intervention For Endpoint reduction in hypertension (LIFE): A randomised trial against atenolol. Lancet 359 (2002) 995-1003
28. Chrysant S.G., and Chrysant G.S. Clinical experience with angiotensin receptor blockers with particular reference to valsartan. J Clin Hypertens (Greenwich) 6 (2004) 445-451
29. Malmqvist K., Ohman K.P., Lind L., et al. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: The Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). J Cardiovasc Pharmacol 42 (2003) 719-726
30. Thürmann P.A., Kenedi P., Schmidt A., et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 98 (1998) 2037-2042
31. Cuspidi C., Muiesan M.L., Valagussa L., et al., for the CATCH Investigators. Comparative effects of cande sartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: The Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) Study. J Hypertens 20 (2002) 2293-2300
32. Chrysant S.G. Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today (Barc) 40 (2004) 791-801
33. Kjeldsen S.E., Dahlöf B., Devereux R.B., et al., for the LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288 (2002) 1491-1498
34. Lithell H., Hansson L., Skoog I., et al., for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized doubleblind intervention trial. J Hypertens 21 (2003) 875-886
35. Papademetriou V., Farsang C., Elmfeldt D., et al., for the Study on Cognition and Prognosis in the Elderly Study Group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 44 (2004) 1175-1180
36. Schrader J., Lüders S., Kulschewski A., et al., for the MOSES Study Group. Morbidityand Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 36 (2005) 1218-1226
37. Mochizuki S., Dahlöf B., Shimizu M., et al., for the Jikei Heart Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomized, openlabel, blinded endpoint morbiditymortality study. Lancet 369 (2007) 1431-1439
38. Chrysant S.G. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: Clinical implications. J Clin Hypertens (Greenwich) 9 (2007) 454-459
39. Viberti G., Wheeldon N.M., and for the Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106 (2002) 672-678
40. Lewis E.J., Hunsicker L.G., Clarke W.R., et al., for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
41. Brenner B.M., Cooper M.E., de Zeeuw D., et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
42. Parving H.H., Lehnert H., Bröhner-Mortensen J., et al., for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
43. Fogari R., Derosa G., Zoppi A., et al. Effect of telmisartan-amloclipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 20 (2007) 417-422
44. Parving H.H., Persson E., Lewis J.B., et al., for the AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358 (2008) 2433-2446
45. Doulton T.W., He F.J., and MacGregor G.A. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45 (2005) 880-886
46. Yusuf K., Teo K.K., Pogue J., et al., for the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
47. Grundy S.M., Cleeman J.I., Daniels S.R., et al., for the American Heart Association and the National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752
48. Kumanyika S.K., Obarzanek E., Stettler N., et al., for the American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention. Population-based prevention of obesity: The need for comprehensive promotion of healthful eating, physical activity, and energy balance: A scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the Expert Panel on Population and Prevention Science). Circulation 118 (2008) 428-464
49. Grundy S.M., Pasternak R., Greenland P., et al. Assessment of cardiovascular risk by use of multiple risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College ofCardiology. Circulation 100 (1999) 1481-1492
50. Eyre H., Kahn R., Robertson R.M., et al., for the American Cancer Society, the American Diabetes Association, the American Heart Association. Preventing cancer, cardiovascular disease, and diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 109 (2004) 3244-3255
51. Markus M.R., Stritzke J., Lieb W., et al. Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function: The MONICA/KORA Augsburg study. J Hypertens 26 (2008) 2040-2049
52. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006) 251-259
53. Shah S.J., and Gheorghiade M. Heart failure with preserved ejection fraction: Treat now by treating comorbidities. JAMA 300 (2008) 431-433
54. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart AttackTrial). Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196]. JAMA 288 (2002) 2981-2997
55. Beckett N.S., Peters R., Fletcher A.E., et al., for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 (2008) 1887-1898
56. Wachtell K., Ibsen H., Olsen M.H., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 139 (2003) 901-906
57. Giles T.D., Oparil S., Silfani T.N., et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 9 (2007) 187-195
58. Weir M.R., Levy D., Crikelair N., et al. Time to achieve blood-pressure goal: Influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens 20 (2007) 807-815
59. Chrysant S.G., Melino M., Karki S., et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 30 (2008) 587-604
60. Douglas J.G., Bakris G.L., Epstein M., et al., for the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 163 (2003) 525-541